Background: The American Thyroid Association (ATA) management guidelines for patients
with thyroid nodules and differentiated thyroid cancer (DTC) are highly influential practice …

Abstract The Japan Associations of Endocrine Surgeons has developed the revised version
of the Clinical Practice Guidelines for Thyroid Tumors. This article describes the guidelines …

Radioiodine (131I) therapy of benign thyroid diseases was introduced 70 yr ago, and the
patients treated since then are probably numbered in the millions. Fifty to 90% of …

Soil and water contaminated with radionuclides threaten the environment and public health
during leaks from nuclear power plants. Remediation of radionuclides at the contaminated …

In many parts of the world, incidence of papillary thyroid cancer is increasing faster than any
other malignancy. Most papillary thyroid cancers that are diagnosed are small and are …

Background: Radioiodine remnant ablation (RRA) has traditionally been one of the
cornerstones of differentiated thyroid cancer (DTC) treatment. The decision to use RRA in …

Background Two large randomised trials of patients with well-differentiated thyroid cancer
reported in 2012 (HiLo and ESTIMABL1) found similar post-ablation success rates at 6–9 …

This review traces the development of targeted radionuclide therapy (TRT)(the Magic Bullet)
from the discovery of radioactivity in nature and the subsequent discovery of artificial …

The last decade has seen a renewed interested in a risk-adapted approach to the
management of differentiated thyroid cancer (DTC), in which specific treatment and follow …

Background In ESTIMABL1, a randomised phase 3 trial of radioactive iodine (131 I)
administration after complete surgical resection in patients with low-risk thyroid cancer, 92 …